Brief: Rocket Pharmaceuticals Announces Closing Of Sale Of Rare Pediatric Disease Priority Review Voucher For $180 Million
12/06/2026 12:03
BRIEF-Rocket Pharmaceuticals Announces Closing Of Sale Of Rare Pediatric Disease Priority Review Voucher For $180 Million June 12 (Reuters) - Rocket Pharmaceuticals Inc RCKT.O:
ROCKET PHARMACEUTICALS ANNOUNCES CLOSING OF SALE OF RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER FOR $180 MILLION
Source text: ID:nBw8vlRNfa
Further company coverage: RCKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket Pharmaceuticals
See all newsRocket Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Brief: Rocket Pharmaceuticals Q2 EPS USD 1.08